|
1
|
Parkin DM, Bray F, Ferlay J and Pisani P:
Global cancer statistics, 2002. CA Cancer J Clin. 55:74–108. 2005.
View Article : Google Scholar
|
|
2
|
Von Dongen GA and Snow GB: Prospectives
for future studies in head and neck cancer. Eur J Surg Oncol.
23:485–491. 1997.
|
|
3
|
Gross L: Immunological defect in aged
population and its relationship to cancer. Cancer Res. 18:201–204.
1965.PubMed/NCBI
|
|
4
|
Ngwenya BZ and Yamamoto N: Activation of
peritoneal macrophages by lysophosphatidylcholine. Biochim Biophys
Acta. 839:9–15. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Yamamoto N, Naraparaju VR and Urade M:
Prognostic utility of serum α-N-acetylgalactosaminidase and
immunosuppression resulted from deglycosylation of serum Gc protein
in oral cancer patients. Cancer Res. 57:295–299. 1997.
|
|
6
|
Yamamoto N and Hoober JK: Tumoricidal
capacities of macrophages photodynamically activated with
hematoporphyrin derivative. Photochem Photobiol. 56:245–250. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Fidler JJ and Schroit AJ: Recognition and
destruction of neoplastic cells by activated macrophages:
discrimination of altered self. Biochim Biophys Acta. 948:151–173.
1988.PubMed/NCBI
|
|
8
|
Keller R: The macrophage response to
infectious agents: mechanisms of macrophage activation and tumor
cell killing. Res Immunol. 144:271–273. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Klostergard J: Macrophage tumoricidal
mechanisms. Res Immunol. 144:274–276. 1993. View Article : Google Scholar
|
|
10
|
Yamamoto N and Naraparaju VR:
Immunotherapy of BALB/c mice bearing Ehrlich ascites tumor with
vitamin D-binding protein-derived macrophage activating factor.
Cancer Res. 57:2187–2192. 1997.PubMed/NCBI
|
|
11
|
Yamamoto N, Suyama H, Nakazato H, Yamamoto
NY and Koga Y: Immunotherapy of metastatic colorectal cancer with
vitamin D-binding protein-derived macrophage activating factor,
GcMAF. Cancer Immunol Immunother. 57:1007–1016. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Yamamoto N, Suyama H, Yamamoto NY and
Ushijima N: Immunotherapy of metastatic breast cancer patients with
vitamin D-binding protein-derived macrophage activating factor
(GcMAF). Int J Cancer. 122:461–467. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yamamoto N, Suyama H and Yamamoto N:
Immunotherapy for prostate cancer with Gc protein-derived
macrophage-activating factor, GcMAF. Transl Oncol. 1:65–72. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Yamamoto N, Willett NP and Lindsay DD:
Participation of serum proteins in the inflammation-primed
activation of macrophages. Inflammation. 18:311–322. 1994.
View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Link RP, Perlman KL, Pierce EA, Schnoes HK
and DeLuca HF: Purification of human serum vitamin D-binding
protein by 25-hydroxyvitamin D3-Sepharose chromatography. Anal
Biochem. 157:262–269. 1986. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Yamamoto N and Kumashiro R: Conversion of
vitamin D3 binding protein (group-specific component) to a
macrophage activating factor by the stepwise action of
beta-galactosidase of B cells and sialidase of T cells. J Immunol.
151:2794–2802. 1993.
|
|
17
|
Yamamoto N: Structural definition of a
potent macrophage activating factor derived from vitamin D3-binding
protein with adjuvant activity for antibody production. Mol
Immunol. 33:1157–1164. 1996. View Article : Google Scholar
|
|
18
|
Nishimura N, Urade M, Hashitani S, et al:
Increased expression of cyclooxygenase (COX)-2 protein in
DMBA-induced hamster cheek pouch carcinogenesis and chemopreventive
effect of a selective COX-2 inhibitor celecoxib. J Oral Pathol Med.
33:614–621. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Segawa E, Hashitani S, Toyohara Y, et al:
Inhibitory effect of sulindac on DMBA-induced hamster cheek pouch
carcinogenesis and its derived cell line. Oncol Rep. 21:869–874.
2009.PubMed/NCBI
|
|
20
|
Odukoya O, Schwartz J, Weichselbaum R and
Shklar G: An epidermoid carcinoma cell line derived from hamster
7,12-dimethylbenz(α)anthracene-induced buccal pouch tumors. J Natl
Cancer Inst. 71:1253–1264. 1983.
|
|
21
|
Zbar B and Tanaka T: Immunotherapy of
cancer: regression of tumors after intralesional injection of
living Mycobacterium bovis. Science. 172:271–273. 1971.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Morton D, Eibler FR, Malmgren RA and Wood
WC: Immunological factors which influence response to immunotherapy
in malignant melanoma. Surgery. 68:158–164. 1970.PubMed/NCBI
|
|
23
|
Yamamoto N and Ngwenya BZ: Activation of
mouse peritoneal macrophages by lysophospholipids and ether
derivatives of neutral lipids and phospholipids. Cancer Res.
47:2008–2013. 1987.PubMed/NCBI
|
|
24
|
Yamamoto N, Ngwenya BZ and Pieringer PA:
Activation of macrophages by ether analogues of lysophospholipids.
Cancer Immunol Immunother. 25:185–192. 1987. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yamamoto N, St Claire DA Jr, Homma S and
Ngwenya BZ: Activation of mouse macrophages by alkylglycerols,
inflammation products of cancerous tissues. Cancer Res.
48:6044–6049. 1988.PubMed/NCBI
|
|
26
|
Homma S and Yamamoto N: Activation process
of macrophage after in vitro treatment of mouse lymphocytes with
dodecylglycerol. Clin Exp Immunol. 79:307–313. 1990. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Homma S, Yamamoto M and Yamamoto N:
Vitamin D binding protein (group-specific component, Gc) is the
sole serum protein required for macrophage activation after
treatment of peritoneal cells with lysophosphatidylcholine. Immunol
Cell Biol. 71:249–257. 1993. View Article : Google Scholar
|
|
28
|
Naraparaju VR and Yamamoto N: Roles of
beta-galactosidase of B lymphocytes and sialidase of T lymphocytes
in inflammation-primed activation of macrophages. Immunol Lett.
43:143–148. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yamamoto N and Homma S: Vitamin D3 binding
protein (group-specific component) is a precursor for the
macrophage-activating signal factor from
lysophosphatidylcholine-treated lymphocytes. Proc Natl Acad Sci
USA. 88:8539–8543. 1991. View Article : Google Scholar
|
|
30
|
Yamamoto N, Homma S, Haddad JG and
Kowalski MN: Vitamin D3 binding protein required for in vitro
activation of macrophages after dodecylglycerol treatment of mouse
peritoneal cells. Immunology. 74:420–424. 1991.PubMed/NCBI
|
|
31
|
Yamamoto N, Homma S and Millman I:
Identification of the serum factor required for in vitro activation
of macrophage – role of vitamin D3-binding protein (group specific
component, Gc) in lysophospholipid activation of mouse peritoneal
macrophages. J Immunol. 147:273–280. 1991.PubMed/NCBI
|
|
32
|
Zhang S, Cordon-Cardo C, Zhang HS, et al:
Selection of tumor antigens as targets for immune attack using
immunohistochemistry. I Focus on gangliosides. Int J Cancer.
73:42–49. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Zhang S, Zhang HS, Cordon-Cardo C, et al:
Selection of tumor antigens as targets for immune attack using
immunohistochemistry. II Blood group-related antigens. Int J
Cancer. 73:50–56. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Zhang S, Zhang HS, Cordon-Cardo C,
Ragupathi G and Livingston PO: Selection of tumor antigens as
targets for immune attack using immunohistochemistry. III Protein
antigen. Clin Cancer Res. 4:2669–2676. 1998.PubMed/NCBI
|
|
35
|
Musselli C, Ragupathi G, Gilewski T,
Panageas KS, Spinat Y and Livingston PO: Reevaluation of the
cellular immune response in breast cancer patients vaccinated with
MUC1. Int J Cancer. 97:660–667. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Ngwenya BZ and Yamamoto N: Effects of
inflammation products on immune systems: lysophosphatidylcholine
stimulates macrophages. Cancer Immunol Immunother. 21:174–182.
1986. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Yamamoto N, Urade M and Ueda M: Potent
tumoricidal capacity of macrophages activated by Gc protein-derived
macrophage activating factor (GcMAF) and its therapeutic efficacy
for prostate, breast and colorectal cancers. J Immunother.
28:6422005. View Article : Google Scholar
|
|
38
|
Yamamoto N and Ueda M: Therapeutic
efficacy of vitamin D-binding protein (Gc protein)-derived
macrophage activating factor (GcMAF) for prostate and breast
cancers. Immunology. Medmond Ltd; Bologna, Italy: pp. 201–204.
2004
|
